Literature DB >> 10026397

Prevalence of hepatitis C virus antibodies and cryoglobulinemia in patients with leukocytoclastic vasculitis.

E Güngör1, A Cirit, N Alli, G Karakayali, G Gür, F Artüz.   

Abstract

BACKGROUND: Several dermatologic manifestations of hepatitis C virus (HCV) infection have been described. The association of HCV infection, essential mixed cryoglobulinemia and leukocytoclastic vasculitis (LV) have been published mainly in case reports.
OBJECTIVE: The aim of the present study was to determine the prevalence of HCV infection and cryoglobulinemia in patients with LV.
METHODS: Twenty-five cases of LV were tested for anti-HCV antibodies by means of a third-generation enzyme-linked immunosorbent assay, and cryoglobulins were detected by the precipitation method. Thirty healthy volunteers served as control group.
RESULTS: Anti-HCV antibodies were detected in 2/25 patients with LV (8%) and none of the control group. Cryoglobulinemia was detected in 1 patient with LV and none in the control group.
CONCLUSION: Although no significant difference between patients and the control group was detected, the prevalence of anti-HCV antibodies in LV patients is as high as 8%. Considering this, it seems reasonable to investigate the presence of HCV in unexplained cases of LV.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10026397     DOI: 10.1159/000018059

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  Cutaneous necrotizing vasculitis associated with hepatitis C virus infection.

Authors:  Amer A Alkhatib; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2007-04-03       Impact factor: 3.199

2.  An interesting rash: leucocytoclastic vasculitis with type 2 cryoglobulinaemia.

Authors:  Gurdeep Singh Mannu
Journal:  JRSM Short Rep       Date:  2010-11-22

Review 3.  Dermatologic Extrahepatic Manifestations of Hepatitis C.

Authors:  Bhavtosh Dedania; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2015-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.